In­ovio spin­out plans piv­otal study for can­cer vac­cine as it touts al­ter­na­tive take on PhIb/IIa liv­er can­cer da­ta

In­ovio spin­out Ge­neos Ther­a­peu­tics said Tues­day that it has three new par­tial re­spons­es and one case of sta­ble dis­ease from a mid-stage liv­er can­cer tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER